Back to News
Market Impact: 0.2
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Source: businesswire.com
Healthcare & BiotechProduct Launches
Bristol Myers Squibb announced it will present the first results for ZENBEXUS (iberdomide) combined with daratumumab from the Phase 3 EXCALIBER-RRMM trial in relapsed or refractory multiple myeloma. The headline does not disclose efficacy, safety, or financial results, limiting immediate read-through for BMS shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
BMY0.55
More News
- Anthropic Goes Big on Compute, Microsoft Rethinks AI
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Details on U.S.-China trade negotiations coming Monday, USTR Greer says
- Meta's 'powerful breakout' sets up a unique trading strategy, says Mike Khouw
- At Meta Connect, the company’s smart glasses were everywhere